Semax Dosage: What the Research Used and Why No US Dose Is Established

Semax dosage is one of the most searched questions about the peptide, and one of the hardest to answer responsibly. Semax is a registered intranasal medicine in Russia, so formulations and regimens exist there. In the US it is not FDA-approved, FDA's July 2026 review found no human pharmacokinetic data by any route, and FDA proposed that it not be added to the 503A Bulks List. This guide explains what Semax dosing looks like in the research literature, what is and is not known, and why there is no established US dose.

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

The Short Answer on Semax Dosage

There is no established US dose of Semax. It has no FDA label, no US dose-finding trials, and — per FDA's 2026 review — no published human pharmacokinetic studies. The dosing information that does exist comes from its Russian registration and Russian clinical studies, which used intranasal formulations. Those regimens are not a US standard, and figures that circulate online (especially for injection) should not be treated as clinical guidance.

How Semax Is Formulated in Russia

In Russia, Semax is supplied as an intranasal solution in two strengths:

The existence of two strengths reflects the range of indications for which the drug is registered there: the lower strength for cognitive uses and the higher strength for acute neurological care, where it is used alongside standard treatment. Specific daily amounts and course lengths are set by the Russian product labeling and prescribing physician; they are not reproduced here because they are not a validated US regimen.

What the Clinical Studies Used

The human Semax literature is predominantly Russian and almost entirely intranasal. Studies have examined its use in ischemic stroke, cognitive impairment, and attention-related conditions, typically over short treatment courses. Two features of this literature matter for dosing:

• The route is intranasal. FDA's 2026 review noted that the only route discussed in the clinical literature was intranasal — and that the nominated US route was subcutaneous, for which there are no safety data.
• The substance form is often unclear. FDA found that published studies frequently did not specify whether Semax free base or Semax acetate was used, which matters for dose equivalence.

Why There Is No US Dose

With none of those in place, a US dose cannot be derived from evidence. Translating a Russian intranasal strength into an injectable dose, in particular, has no pharmacokinetic basis.

Semax Nasal Spray vs Injection

Much US marketing presents Semax as an injectable. That is a departure from the drug's studied use: the clinical record is intranasal. Intranasal delivery is thought to allow partial access to the brain along the olfactory and trigeminal pathways, while an injected peptide would face systemic breakdown and the blood–brain barrier. The two routes are not interchangeable, and there is no human data on injected Semax. For background on the nasal route, see the Semax page.

Regulatory Status

At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that Semax (free base and acetate) not be added to the 503A Bulks List. FDA cited:

• insufficient characterization of the substance;
• no human pharmacokinetic data;
• no safety data for the proposed subcutaneous route;
• a rodent finding that Semax potentiated amphetamine-induced dopamine release.

Russian registration does not confer US approval or a compounding pathway. As a result, compounded access to Semax in the US is in serious doubt; if lawful access were ever confirmed, any dosing decision would still rest on the prescriber in the absence of US data. See Semax and the FDA 503A decision, the earlier Semax FDA status explainer, and our FDA peptide status tracker for current status.

Safety Considerations Relevant to Dosing

• Stimulant interaction signal. The amphetamine-potentiation finding in mice is relevant for patients using stimulant medications or with a history of substance misuse.
• Uncharacterized product. Without substance-specific quality attributes, product-to-product variation in identity and purity is a genuine risk, especially for "research chemical" sources.
• Reported effects. The clinical literature describes adverse effects as generally mild (nasal irritation is most often mentioned), but FDA concluded the human safety profile is insufficiently characterized.
• Pregnancy and breastfeeding. No data.

Semax Compared With Selank Dosing

Selank, Semax's frequent companion, is also a Russian intranasal peptide but sits differently with the FDA (Category 1 on the tracker). It has no established US dose either; its background is on the Selank page, and the two are compared in Semax and Selank.

Frequently Asked Questions

What is the standard Semax dosage?

There is no US standard. Semax is registered in Russia as an intranasal solution (0.1% and 1% strengths), and Russian labeling sets its regimens. It has no FDA label, and FDA found no published human pharmacokinetic data, so no US dose is established.

Is Semax taken as a nasal spray or an injection?

Its studied use is intranasal. Injection is common in US marketing, but FDA found no safety data for the subcutaneous route, and nasal and injected doses are not interchangeable.

Why doesn't this guide give a dose in milligrams?

Because no evidence-based US dose exists. Converting a Russian intranasal strength into an injectable amount has no pharmacokinetic basis, and figures online are not validated.

Can Semax be compounded in the US?

FDA proposed in July 2026 that Semax not be added to the 503A Bulks List, so compounded access is in serious doubt. Check the FDA peptide status tracker for current status.

What are Semax's side effects?

Published studies describe generally mild effects such as nasal irritation, but FDA concluded the safety profile is insufficiently characterized. It also flagged a rodent signal of amphetamine potentiation.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers. For the wider cognitive-peptide landscape, see our nootropic peptides guide.